CPhI Annual Expert Industry Report (Part ii): Live from CPhI Worldwide
Germany (ots/PRNewswire)
CPhI expert industry panel members highlight future implications for pharma
in final part of CPhI industry report
Industry to encounter drug shortages and threat of adulterated products, with pharma shifting focus to orphan drug development, low cost products and continuous
processing
Report's expert highlights
Girish Malhotra, President at EPCOT International:
- Pharma to switch to low-cost drugs that have a larger customer base
- Industry is at risk from possible drug shortages as weaker players in
developing countries fail to meet regulatory requirements
- Minimizing process inefficiencies through PAT and QbD will lead to 20-25%
savings of global revenues
- Continuous processing is forecast to revolutionise manufacturing with reduced
costs, increased sustainability and consistently higher product quality
- Alternatives for APIs include modular technologies in place of continuous
processing
Prabir Basu, Independent Consultant and a former Director of NIPTE:
- Regulatory environment needs to change to offer incentives for achieving
excellence- presently pharma is focussed on non-compliance
- FDA should focus resources on regions with a likelihood of failure
- FDA could learn from 'trust and verify'-style OHSA Voluntary Protection
Program
- Biggest threat to industry is that most companies get ingredients that are not
being inspected
- cGMP needs to be extending to excipient manufacture.
Emil Ciurczak, Principal at Doramax Consulting:
- Speed of development from lab scale to small scale manufacturing is dramatically accelerating - Batch processing may now be a thing of the past - In 10-15 years it will be impossible to tell if one is in a generics or branded pharmaceutical facility - Generics race will lead to smaller number of larger generics companies - Increased collaboration between FDA and EMA, with QbR adoption ensuring generics manufacturers improve process knowledge-base
Hedley Rees, Principal at PharmaFlow:
- Regulation with such a prescriptive approach is not actively targeting
mal-intent within the supply chain
- Regulators should raise the bar for CMC filing at the IND/CTA stage to ensure
only the most promising molecules enter the clinic
- Improvements in in silico and in vitro testing will help to improve
predictive capabilities
- Track and trace under FDASIA to support supply chain improvements but a
change in behaviour is needed to truly ensure safety
- Contract research and manufacturing sector needs to take an active role in
innovation and share some of the costs and risks
CPhI Worldwide [http://www.cphi.com] and CPhIPharma Evolution [http://www.pharmaevolution.com], part of UBM Live's Pharmaceutical Portfolio, announce the release of the remaining findings of its annual report- with contributions from expert industry panel members Prabir Basu, Independent Consultant and former Director of NIPTE, Girish Malhotra, President at EPCOT International, Emil Ciurczak, Principal at Doramax Consulting and Hedley Rees, Principal at PharmaFlow.
(Logo: http://photos.prnewswire.com/prnh/20130723/629764-a )
The remaining four articles of the annual report highlight the effects that increased regulation and new practices, including QbD, are likely to have on the global marketplace, alongside continuous processing and risks in the supply chain.
Girish Malhotra's analysis suggests that alongside these quality and process issues, pharma is likely to change its business model towards developing lower-cost drugs that have a larger customer base, with big pharma revenues increasingly coming from orphan drugs.
However, he also sees risks of an increasingly stringent regulatory environment, with drug shortages envisaged as consolidation occurs amongst weaker players in developing countries.
Prabir Basu, in contrast, sees the greatest threat to the industry coming from uninspected ingredients and argues that it is essential that cGMP be extended to excipient manufacture.
Hedley Rees echoes these thoughts and believes that the current prescriptive approach is not adequately targeting 'mal-intent in the supply chain'.
One solution, Basu believes, to the regulatory minefield would be for the FDA to implement a 'trust and verify'-style OHSA Voluntary Protection Program, which would provide flexibility for cGMP sites to make modifications whilst accelerating the implementation of Operational Excellence (OpEx) without fear of shutdown. The FDA should also focus its resources on regions with the greatest likelihood of failure.
"Track and trace under FDASIA will also help to drive supply chain improvements but a change in behaviour is also needed to ensure safety. Industry is far too reliant on regulation as an excuse for not taking the initiative," Hedley Rees notes.
Another major problem, Prabir Basu identifies, is that the current regulatory environment does not incentivise achieving excellence and is rather more focused on non-compliance. Girish identified a solution to this and believes that the implementation of PAT and QbD will not only lead to higher standards, but will help remove process inefficiencies- leading to global revenue savings of 20-25%.
Emil Ciurczak also sees the benefits of these new methodologies and states that in 10-15 years' time, it will be impossible to tell if a site is generic or a branded pharmaceutical facility.
These improvements in standards will inevitably come at the cost of market consolidation, with a generics race underway ultimately leading to a smaller number of larger generics companies. An essential element to improve standards across generics manufacturing will be the adoption of QbR and ever-closer collaboration between the FDA and EMA.
Another benefit of QbD/PAT is the ability to vary experimental conditions, which should allow development work to progress from laboratory scale to small scale manufacturing more quickly. Hedley Rees supported this, adding that supply chain quality should be brought into the equation at the early development stage, with poorly characterized molecules becoming redundant before development work. He also suggests regulators should raise the bar for CMC filing at the IND/CTA stage to help ensure that only the promising molecules enter the clinic.
The final area highlighted by several of the panel members, including Girish Malhotra and Emil Ciurczak, is the potential for continuous processing to revolutionise manufacturing with reduced costs, increased sustainability and constantly higher product quality, with the advent of QbD and PAT producing an enabling environment so that batch processing may be a thing of the past.
Chris Kilbee- Group Director, Pharma, commented: "The remaining findings from our CPhIPharma Evolution annual report show that over the next few years stringent regulations and practices such as QbD are prominently shaping the global marketplace. A large number of our experts emphasise QbD in playing an increasingly large role to ensure products are manufactured to consistently high standards of quality that align with all regulatory bodies. But with increased standards does come short-term risks of product shortages, however, in the longer term we can expect huge revenues savings from these techniques, and in as little as 10-years' time standards at generics and branded sites will be indistinguishable."
For full copies of the submission and overall reports please visit: http://www.cphi.com
Notes to editors
About CPhIPharma Evolution annual report and expert industry panel
Earlier this year, CPhI launched a major new initiative with the introduction of its annual report published in cooperation with Pharma Evolution- written by a panel of world-leading experts across the pharmaceutical supply chain.
The vision was to harness the power of CPhI's independent position within the industry so that it could produce unbiased analysis of the global pharmaceutical industry and help bring different perspectives together.
The annual report utilises expert in-depth essays, looking at future contingencies. Experts were given carte blanche to evaluate current industry practices and examine the future implications for the industry.
About CPhI
CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, China, India, Japan, Southeast Asia, Russia and South America co-located with ICSE for contract services, P-MEC for machinery, equipment & technology, InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com and hosts a global community with news and analysis at PharmaEvolution.com.
For more information visit: http://www.cphi.com
The UBM Live annual schedule of Pharmaceutical events also includes CPhI Worldwide, ICSE, P-MEC Europe and InnoPack ; CPhI and P-MEC India (3-5 December, 2013 at the Bombay Exhibition Centre in Mumbai); CPhI, ICSE, P-MEC, BioPh and Pharmatec Japan ; CPhI Russia and IPhEB (16-17 April, 2014 in St Petersburg, Russia); CPhI, P-MEC and Innopack South East Asia (20-22 May, 2014 in Jakarta, Indonesia); CPhI Istanbul (4-6 June, 2014, Turkey) and CPhI, Hi and Fi, ICSE, P-MEC, BioPh and LabWorld China (26-28 June, 2014 at SNIEC, Shanghai, China), CPhI South America (5-7 August 2014 at Expo Centre Norte, Sao Paulo- Brazil).
About CPhIPharma Evolution
CPhIPharma Evolution (http://www.pharmaevolution.com) launched in February 2013 as a global online community where professionals from across the pharmaceutical manufacturing sector can talk with their peers and share best-practices and regulatory updates across the pharmaceutical ingredient and contract manufacturing space. Pharma Evolution is the new go-to community for industry professionals to exchange thoughts and network on key areas including: formulation, APIs, excipients, drug delivery, R&D, manufacturing and quality, packaging and anti-counterfeiting, regulatory compliance, and outsourcing and supply chain management. Pharma Evolution was created as an extension of CPhI's global events business as a forum and resource for pharmaceutical executives to employ 365 days a year. Pharma Evolution is published by CPhI and UBM DeusM (http://www.deusm.com), the marketing services division of UBM specializing in building and operating highly engaged communities of qualified users within specialist B2B markets, using a strategy of best-practices focused on content and technology.
About UBM Live
UBM Live connects people and creates opportunities for companies across five continents to develop new business, meet customers, launch new products, promote their brands, and expand their market. Through premier brands such as TFM&A, Internet World, IFSEC, MD&M, CPhI, Cruise Shipping Miami, the Concrete Show, and many others, UBM Live exhibitions, conferences, awards programs, publications, Websites, and training and certification programs are an integral part of the marketing plans of companies across more than 20 industry sectors.
For media enquiries, please contact: Alex Heeley or Tristan Jervis De Facto Communications T: +44-(0)207-203-6745 / 6740 E: a.heeley@defacto.com / t.jervis@defacto.com
Photo: http://photos.prnewswire.com/prnh/20130723/629764-a